Steven Kim, MD
Family Practice · Sunnyvale
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 31
- 8 carriers
- Offices
- 4
On the public record
- 1 Medical Board action on record
Offices
4 locations · Inspire Medical Group of California PC · Bay Area Community Health · Center for Cardiovascular Care A Medical Corporation
Looking this up.
Plans that list them
31 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kim’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
31 of 31 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G69347 · Current
Licensed to practise in California · since 1990 · expires 2027-09-30 · University of California, Davis School of Medicine. Board flags: Probation Completed.
Public record actions
| 2019-07-10 | Board disciplineDiscipline | Probation completed. · 03 2012228203 |
Original Medicare doctor bills
$15,338
Medicare paid this office $15,338 for 109 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 43 | $5,585 | $130 |
| New patient visit (30+ min) | 50 | $4,305 | $86 |
| Short return visit (20+ min) | 28 | $2,416 | $81 |
Who their Medicare patients are
109 Original Medicare patients in 2024. Average age 76 · Women 54% · Also on Medicaid 14% · Health risk score 0.70. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 75% · Diabetes 39% · Coronary heart disease 15% · Chronic kidney disease 15%.
The office billed $45,243, Medicare allowed $22,128 and paid $15,338; for 149 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 109 | 149 | 76 | 0.70 | $45,243 | $15,338 |
| 2021 | 21 | 23 | 73 | 0.56 | $6,440 | $2,000 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Medicaid work
$430,639 in 2023
Medicaid paid $430,639 for 5,104 billed services this clinician did in 2023, up to 424 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,583 | $414,778 |
| Short return visit (20+ min) | 2,459 | $11,100 |
| Return visit (30+ min) | 125 | $2,437 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 19 | $1,021 |
| Hemoglobin A1C level | 218 | $810 |
| Hemoglobin; by copper sulfate method, non-automated | 190 | $244 |
| Blood glucose (sugar) level | 136 | $237 |
| New patient visit (30+ min) | 24 | $13 |
| HEMOGLOBIN A1C LEVEL >9.0% | 28 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 59 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 16 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 55 | $0 |
| 2023 | 5,104 | 17 | 424 | $430,639 |
| 2022 | 10,895 | 20 | 489 | $962,520 |
| 2021 | 5,363 | 18 | 392 | $509,049 |
| 2020 | 5,294 | 13 | 363 | $270,322 |
| 2019 | 1,772 | 3 | 131 | $215,223 |
| 2018 | 2,628 | 3 | 387 | $324,848 |
See the largest Medicaid services in earlier years
2022
| Clinic visit/encounter, all-inclusive | 3,652 | $947,682 |
| Short return visit (20+ min) | 5,429 | $9,653 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 87 | $1,315 |
| Return visit (30+ min) | 199 | $690 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 49 | $676 |
| Short return visit | 66 | $662 |
| Hemoglobin A1C level | 108 | $584 |
| New patient visit (30+ min) | 114 | $521 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 55 | $244 |
| Hemoglobin; by copper sulfate method, non-automated | 146 | $224 |
| Blood glucose (sugar) level | 66 | $157 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 60 | $113 |
2021
| Clinic visit/encounter, all-inclusive | 2,025 | $504,413 |
| Short return visit (20+ min) | 2,477 | $2,974 |
| Short return visit | 98 | $288 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 48 | $213 |
| Hemoglobin; by copper sulfate method, non-automated | 170 | $210 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 86 | $209 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 83 | $173 |
| Pure tone audiometry (threshold); air only | 23 | $166 |
| Return visit (30+ min) | 34 | $153 |
| Hemoglobin A1C level | 38 | $107 |
| New patient visit (30+ min) | 56 | $63 |
| Blood glucose (sugar) level | 28 | $38 |
2020
| Clinic visit/encounter, all-inclusive | 1,421 | $259,710 |
| Short return visit (20+ min) | 2,998 | $8,156 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 190 | $1,062 |
| Return visit (30+ min) | 72 | $638 |
| Pure tone audiometry (threshold); air only | 25 | $360 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 29 | $288 |
| HEMOGLOBIN | 94 | $108 |
| Bilateral quantitative screening test of visual acuity | 18 | $0 |
| New patient visit (30+ min) | 22 | $0 |
| OFF/OP EST MAY X REQ PHY/QHP | 310 | $0 |
| Short return visit | 67 | $0 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 26 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 1,476 | $212,367 |
| Short return visit (20+ min) | 280 | $2,668 |
| Return visit (30+ min) | 16 | $188 |
2018
| Clinic visit/encounter, all-inclusive | 2,159 | $310,242 |
| Short return visit (20+ min) | 447 | $14,556 |
| HEMOGLOBIN | 22 | $50 |
Drugs they prescribed that Part D paid
$54,727
Pharmacies billed $54,727 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
768 generic and fewer than 11 brand-name prescriptions · $54,727 in drug cost · 26 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rosuvastatin | 34 | $855 | $25 |
| Atorvastatin | 60 | $742 | $12 |
| Amlodipine Besylate | 61 | $547 | $9 |
| Losartan-Hydrochlorothiazide | 28 | $413 | $15 |
| Omeprazole | 27 | $391 | $14 |
See all 23 drugs
| Rosuvastatin | 34 | $855 | $25 |
| Atorvastatin | 60 | $742 | $12 |
| Amlodipine Besylate | 61 | $547 | $9 |
| Losartan-Hydrochlorothiazide | 28 | $413 | $15 |
| Omeprazole | 27 | $391 | $14 |
| Losartan | 28 | $372 | $13 |
| Metformin Hcl Er | 61 | $365 | $6 |
| Metoprolol | 16 | $342 | $21 |
| Levothyroxine | 19 | $290 | $15 |
| Pantoprazole | 15 | $237 | $16 |
| Pravastatin | 18 | $234 | $13 |
| Metformin | 25 | $227 | $9 |
| Simvastatin | 18 | $190 | $11 |
| Finasteride | 11 | $184 | $17 |
| Lisinopril | 15 | $169 | $11 |
| Atenolol | 16 | $146 | $9 |
| Gabapentin | 14 | $122 | $9 |
| Hydrochlorothiazide | 13 | $109 | $8 |
| Naproxen | 11 | $108 | $10 |
| Zolpidem | 20 | $76 | $4 |
| Triamcinolone Acetonide | 11 | $34 | $3 |
| Furosemide | 11 | $33 | $3 |
| Amoxicillin | 11 | $23 | $2 |
Year by year
| 2024 | 828 | 205 | None | None | $54,727 |
| 2023 | 746 | 82 | None | 9% | $45,652 |
| 2022 | 996 | 115 | None | 13% | $55,025 |
| 2021 | 602 | 93 | 0% (0) | None | $34,209 |
| 2020 | 675 | 76 | None | None | $32,881 |
| 2019 | 476 | 61 | None | None | $22,639 |
| 2018 | 614 | 66 | None | None | $32,936 |
| 2017 | 366 | 56 | None | 10% | $13,556 |
| 2016 | 163 | 38 | 9% (14) | 7% | $3,380 |
| 2015 | 30 | 12 | None | None | $1,177 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Oxcarbazepine | 16 | $863 | $54 |
| Atorvastatin | 58 | $857 | $15 |
| Rosuvastatin | 11 | $848 | $77 |
| Insulin | 19 | $794 | $42 |
| Levothyroxine | 50 | $729 | $15 |
| Albuterol Sulfate Hfa | 25 | $667 | $27 |
| Gabapentin | 13 | $666 | $51 |
| Metformin | 50 | $570 | $11 |
| Lisinopril | 41 | $499 | $12 |
| Amlodipine Besylate | 33 | $457 | $14 |
| Losartan | 29 | $456 | $16 |
| Tamsulosin | 22 | $401 | $18 |
| Omeprazole | 40 | $360 | $9 |
| Oxybutynin Chloride Er | 15 | $289 | $19 |
| Simvastatin | 22 | $185 | $8 |
| Hydrochlorothiazide | 32 | $171 | $5 |
| Famotidine | 12 | $148 | $12 |
2022: 24 drugs
| Albuterol Sulfate Hfa | 41 | $1,354 | $33 |
| Oxcarbazepine | 25 | $1,234 | $49 |
| Oxybutynin Chloride Er | 28 | $1,051 | $38 |
| Levothyroxine | 73 | $1,026 | $14 |
| Atorvastatin | 73 | $939 | $13 |
| Divalproex Sodium Er | 13 | $927 | $71 |
| Rosuvastatin | 11 | $675 | $61 |
| Glycopyrrolate | 12 | $515 | $43 |
| Gabapentin | 13 | $457 | $35 |
| Famotidine | 38 | $363 | $10 |
| Omeprazole | 33 | $282 | $9 |
| Metformin | 45 | $275 | $6 |
| Losartan | 16 | $254 | $16 |
| Hydroxyzine | 14 | $235 | $17 |
| Lisinopril | 52 | $220 | $4 |
| Pantoprazole | 18 | $201 | $11 |
| Simvastatin | 36 | $182 | $5 |
| Amlodipine Besylate | 22 | $161 | $7 |
| Metoprolol | 14 | $147 | $10 |
| Tamsulosin | 17 | $144 | $8 |
| Hydrochlorothiazide | 27 | $137 | $5 |
| Naproxen | 11 | $96 | $9 |
| Trazodone | 12 | $71 | $6 |
| Triamcinolone Acetonide | 11 | $61 | $6 |
2021: 15 drugs
| Albuterol Sulfate Hfa | 28 | $1,107 | $40 |
| Atorvastatin | 55 | $713 | $13 |
| Levothyroxine | 32 | $539 | $17 |
| Losartan | 17 | $223 | $13 |
| Lisinopril | 31 | $154 | $5 |
| Gabapentin | 15 | $153 | $10 |
| Amlodipine Besylate | 43 | $134 | $3 |
| Metformin | 32 | $123 | $4 |
| Hydrochlorothiazide | 23 | $105 | $5 |
| Tamsulosin | 12 | $99 | $8 |
| Omeprazole | 14 | $79 | $6 |
| Simvastatin | 14 | $71 | $5 |
| Atenolol | 12 | $56 | $5 |
| Naproxen | 11 | $46 | $4 |
| Glipizide | 12 | $42 | $3 |
2020: 21 drugs
| Zenpep | 12 | $11,988 | $999 |
| Albuterol Sulfate Hfa | 20 | $818 | $41 |
| Gabapentin | 17 | $654 | $38 |
| Levothyroxine | 33 | $495 | $15 |
| Atorvastatin | 46 | $481 | $10 |
| Oxybutynin Chloride | 12 | $298 | $25 |
| Tamsulosin | 33 | $234 | $7 |
| Naproxen | 34 | $211 | $6 |
| Metformin | 31 | $185 | $6 |
| Lisinopril | 36 | $181 | $5 |
| Glipizide | 46 | $163 | $4 |
| Losartan | 11 | $160 | $15 |
| Ibuprofen | 21 | $158 | $8 |
| Omeprazole | 11 | $142 | $13 |
| Amlodipine Besylate | 31 | $136 | $4 |
| Montelukast | 18 | $99 | $6 |
| Clopidogrel | 12 | $96 | $8 |
| Carvedilol | 12 | $95 | $8 |
| Atenolol | 20 | $85 | $4 |
| Finasteride | 12 | $85 | $7 |
| Hydrochlorothiazide | 26 | $65 | $3 |
2019: 15 drugs
| Zenpep | 12 | $11,387 | $949 |
| Gabapentin | 24 | $1,838 | $77 |
| Atorvastatin | 33 | $394 | $12 |
| Levothyroxine | 27 | $363 | $13 |
| Oxybutynin Chloride | 12 | $289 | $24 |
| Amlodipine Besylate | 41 | $214 | $5 |
| Chlorhexidine Gluconate | 12 | $157 | $13 |
| Ranitidine | 18 | $146 | $8 |
| Glipizide | 27 | $120 | $4 |
| Omeprazole | 21 | $106 | $5 |
| Lisinopril | 14 | $97 | $7 |
| Metformin | 16 | $93 | $6 |
| Naproxen | 12 | $79 | $7 |
| Atenolol | 21 | $62 | $3 |
| Meloxicam | 12 | $49 | $4 |
2018: 19 drugs
| Januvia | 13 | $5,545 | $427 |
| Vesicare | 11 | $4,078 | $371 |
| Levothyroxine | 32 | $451 | $14 |
| Gabapentin | 21 | $431 | $21 |
| Amlodipine Besylate | 64 | $328 | $5 |
| Lisinopril | 38 | $178 | $5 |
| Metformin | 39 | $174 | $4 |
| Ibuprofen | 14 | $169 | $12 |
| Ranitidine | 18 | $143 | $8 |
| Tamsulosin | 12 | $132 | $11 |
| Pantoprazole | 21 | $116 | $6 |
| Fluticasone Propionate | 12 | $115 | $10 |
| Atenolol | 16 | $105 | $7 |
| Furosemide | 14 | $82 | $6 |
| Omeprazole | 11 | $63 | $6 |
| Glipizide | 17 | $62 | $4 |
| Meloxicam | 12 | $50 | $4 |
| Amoxicillin | 12 | $49 | $4 |
| Hydrochlorothiazide | 11 | $24 | $2 |
2017: 8 drugs
| Ventolin Hfa | 12 | $637 | $53 |
| Metformin | 42 | $158 | $4 |
| Gabapentin | 15 | $145 | $10 |
| Ibuprofen | 15 | $116 | $8 |
| Amlodipine Besylate | 32 | $115 | $4 |
| Lisinopril | 20 | $81 | $4 |
| Glipizide | 11 | $59 | $5 |
| Hydrochlorothiazide | 16 | $37 | $2 |
2016: 1 drug
| Metformin | 15 | $63 | $4 |
Money from drug and device companies
$32 in 2025
| 2025 | 2 | 2 | None | $32 |
| 2024 | 1 | 4 | None | $130 |
| 2023 | 1 | 1 | None | $32 |
| 2021 | 2 | 3 | None | $153 |
| 2019 | 1 | 1 | None | $15 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Dupixent | $17 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $15 | 1 payment
|
See all 2 published payments
| Regeneron Healthcare Solutions | Meals · 2025-10-23 | Dupixent | $17 |
| Exact Sciences | Meals · 2025-09-11 | Cologuard Collection Kit | $15 |
See earlier years (2024, 2023, 2021, 2019)
2024: $130
| Janssen Pharmaceuticals | Spravato | $130 | 4 payments
|
2023: $32
| Boston Scientific | Watchman Flx | $32 | 1 payment
|
2021: $153
| Novo Nordisk | Rybelsus | $134 | 2 payments
|
| Eisai | Lenvima | $19 | 1 payment
|
2019: $15
| Merck Sharp & Dohme | Rotateq | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · A Study To Evaluate the Optimization of the Crs Profile for Glofit+Gemox in R/R Dlbcl · 2025 | Their institution | $33,800 |
Professional record
- NPI
- 1043313992
- Licence
- CA G69347California G69347: Current · expires 2027-09-30
- Trained
- University of California, Davis School of Medicine, 1989
- Group
- Inspire Medical Group of California PC · Bay Area Community Health · Center for Cardiovascular Care A Medical Corporation
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Family medicine (207Q00000X); Federal specialty code 207QA0000X (207QA0000X)
- Mailing address
- 333 W El Camino Real Ste 230, Sunnyvale, CA, 94087
- NPI first listed
- 2006-09-06
- NPI last updated
- 2024-05-23
- NPI record certified
- 2024-05-23
This is when the NPI record was last certified, not a medical board exam.